What's New in the Treatment of Enterococcal Endocarditis? - Wikidata - wikimedia - TriplyDB

What's New in the Treatment of Enterococcal Endocarditis?

What's New in the Treatment of Enterococcal Endocarditis?

http://www.wikidata.org/entity/Q41368979

about

The fibronectin-binding protein EfbA contributes to pathogenesis and protects against infective endocarditis caused by Enterococcus faecalis The fibronectin-binding protein Fnm contributes to adherence to extracellular matrix components and virulence of Enterococcus faecium Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis.Genome-wide Screening Identifies Phosphotransferase System Permease BepA to Be Involved in Enterococcus faecium Endocarditis and Biofilm Formation.Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations.Enterococci and Their Interactions with the Intestinal Microbiome.A retrospective clinical comparison of daptomycin vs daptomycin and a beta-lactam antibiotic for treating vancomycin-resistant Enterococcus faecium bloodstream infections.In vivo and in vitro effects of a ClpP activating antibiotic against vancomycin resistant enterococci.Non-Antimicrobial Drugs: Etodolac as a Possible Antimicrobial or Adjuvant Agent Against ESKAPE Pathogens

P2860

Q36281265-9379F0FF-0917-4F4D-98F1-EEC9007ED441 Q36281286-60291811-826E-4C05-895C-823049D1E922 Q38892614-0378A6E7-45DB-4358-BB9C-95A93544AC7E Q40752566-962266B2-86CD-416F-B5D5-E455C8247D20 Q41695361-6C2BB689-C944-40E1-BBA1-1725E818F55A Q46819823-08555A5F-55AE-47CF-8EA2-CB2343DDA9B4 Q49176485-ABA5AFB5-C4DF-4C9C-9119-27872EECF779 Q54203694-EDA11256-4C3D-41BF-AD41-8E100AFC7AE4 Q57130953-0B5D6959-AA99-4C69-A3E0-41EF3765947F

P2860

What's New in the Treatment of Enterococcal Endocarditis?

http://www.wikidata.org/entity/Q41368979

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

What's New in the Treatment of Enterococcal Endocarditis?

@en

type

label

What's New in the Treatment of Enterococcal Endocarditis?

@en

prefLabel

What's New in the Treatment of Enterococcal Endocarditis?

@en

P1433

Q41368979-B79EA956-A5CB-48EC-BF95-B5A7F8702ABA

P1476

Q41368979-76E1690B-7385-497C-87E1-14A36B26ED83

P2093

Q41368979-1753B8AB-6DB9-4713-9FBA-6BF6CDFD59F8

Q41368979-251F6A9D-66A2-4805-B59E-E2F3EAC344A1

Q41368979-838ABB1D-5A32-4D42-BD54-6BA453985AA6

P2860

Q41368979-03D93A9B-EC3D-4EF4-B8C2-FC7F66ADC198

Q41368979-04E877C5-0AEC-409C-A1F2-95C5D48AF219

Q41368979-0DA941DF-71C1-4314-ADA9-0EE42B82FCF2

Q41368979-0E4CA02A-C5F1-446E-BB05-857AAA521739

Q41368979-0E582639-D290-4611-B203-51314EDF1086

Q41368979-166E7A31-7624-4204-ACB9-F503E8D38752

Q41368979-184F71E9-2EB7-4B30-8205-325982C63B86

Q41368979-23870D33-C8AB-48B7-9184-5592E8B5A16A

Q41368979-263917C1-8771-4E8B-AD14-8DD83AFD4340

Q41368979-26CE66C4-95C3-4A2F-9B1F-518AB83EED3D

P304

Q41368979-D9063F5E-1278-4785-BAE8-73C97EFB15F6

P31

Q41368979-E5FCE93D-EA51-400E-98F0-FFA1D1DCE383

P356

Q41368979-1331EC7A-73A8-47B2-9270-4E8C8CAA1F5E

P433

Q41368979-906EBC82-C477-401C-A639-7D2DE7A5A1CD

P478

Q41368979-531C60E2-0ED5-4C82-A49F-CA01C4D8600A

P50

Q41368979-1CFD74D0-D660-4BC6-9FDB-1B23B9C9F6C7

P577

Q41368979-246A20BD-C570-493B-ADA8-81B3049B6073

P5875

Q41368979-9C98660C-661A-4638-B204-92A7A17D266F

P698

Q41368979-0430B0F2-A0C9-4A91-A73B-EE637C7244A8

P932

Q41368979-61E34A0F-D8A9-4588-8CBD-BBF62ACCB98F

P356

S11908-014-0431-Z

P1433

Current infectious disease reports

P1476

What's New in the Treatment of Enterococcal Endocarditis?

@en

P2093

Barbara E Murray

http://www.w3.org/2001/XMLSchema#string

Cesar A Arias

http://www.w3.org/2001/XMLSchema#string

Masayuki Nigo

http://www.w3.org/2001/XMLSchema#string

P2860

The life and times of the Enterococcus

Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study

Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors

Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia

Genomic and SNP analyses demonstrate a distant separation of the hospital and community-associated clades of Enterococcus faecium

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program.

Success of ampicillin plus ceftriaxone rescue therapy for a relapse of Enterococcus faecalis native-valve endocarditis and in vitro data on double beta-lactam activity.

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence.

Beta-lactamase-producing enterococci.

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

P304

431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11908-014-0431-Z

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

265136260

http://www.w3.org/2001/XMLSchema#string

P698

25165018

http://www.w3.org/2001/XMLSchema#string

P932

4492516

http://www.w3.org/2001/XMLSchema#string